

Virus Name: Congo		Abbreviation: CONV
Status Arbovirus	Select Agent No	SALS Level 4
SALS Basis Level assigned to prototype or wild-type virus. A lower level may be recommended for laboratory strains or geographic variants of the virus with well-defined reduced virulence characteristics, as mentioned in the text.		
Other Information		
Antigenic Group CHF-CON		

SECTION I - Full Virus Name and Prototype Number

Prototype Strain Number / Designation V 3011	Accession Number	Original Date Submitted 10/28/1984
Family Nairovirus	Genus	
Information From B.G. Kirya, G.W. Kafuko	Address East African Virus research Institute, Box 49, Entebbe, Uganda	
Information Footnote Reviewed by editor		

Section II - Original Source

Isolated By (name) Dr. G. Courtois (1,2)	Isolated at Institute Prov. Med. Lab., (Stanleyville) Kisangani	
Host Genus Man	Species	Host Age/Stage 13 years
Sex Male		
<u>Isolated From</u>	<u>Isolation Details</u>	
Serum/Plasma		
Signs and Symptoms of Illness fever, headache, nausea, vomiting, backache, generalized joint pains, photophobia	Arthropod	
Time Held Alive before Inoculation		
Collection Method venepuncture under sterile conditions	Collection Date 3/6/1956	
Place Collected (Minimum of City, State, Country) Prov. Med. Lab. (Stanleyville) Kisangani		
Latitude 0° 33' N	Longitude 25° 14' E	
Macrohabitat	Microhabitat	Method of Storage until Inoculated
Footnotes		

Section III - Method of Isolation

Inoculation Date
3/6/1956

Animal (Details will be in Section 6)
nb mice

Route Inoculated
ic and ip

Reisolation
Not tried

Other Reasons

Homologous Antibody Formation by Source Animal
Not tested

Test(s) Used

Footnotes

Section IV - Virus Properties

Physicochemical

Pieces (number of genome segments)	Infectivity	Sedimentation Coefficients(s) (S)
Percentage wt, of Virion Protein	Lipid	Carbohydrate
Virion Polypeptides: Number	Details	
Non-virion Polypeptides: Number	Details	
Virion Density	Sedimentation Coefficients(s) (S)	
Nucleocapsid Density	Sedimentation Coefficients(s) (S)	

Stability of Infectivity (effects)

pH (infective range)

Lipid Solvent (ether - % used to test) 1:1	After Treatment Titer <=0.5 dex	Control Titer 2.1 dex
Lipid Solvent (chloroform)	After Treatment Titer	Control Titer
Lipid Solvent (deoxycholate)	After Treatment Titer	Control Titer

Other (formalin, radiation)

Virion Morphology

Shape	Dimensions 70-140 nm	
Mean nm	Range nm	
Measurement Method millipore membrane filtration (14)	Surface Projections/Envelope	Nucleocapsid Dimensions, Symmetry

It was screened by CF at 1/5 and 1/40 against hyperimmune antisera to the following African arboviruses without finding any significant relationship:

Bunyamwera	Ingwavuma	Lebombo
Germiston	Simbu	Lumbo
Ilesha	African horsesickness	Mossuril
Olifantsvlei	Bluetongue	Orungo
Shokwe	Chenuda	Nairobi sheep disease
Bwamba	Dakar	Nyamanini
Pongola	Lagos bat	Nyando
Quaranfil	Tanga	Tete
Thogoto	Wad Medani	Witwatersrand

It was also negative with hyperimmune Herpes simmplex antiserum.

Hyperimmune antiserum (V 3011) has been screened at 1/10 by HI with negative results against the following antigens:

Group A	chikungunya, Semliki forest virus, Sindbis
Group B	yellow fever, West Nile, Zika, Banzi
Bunyamwera	(Aedes '43)

Casals [10] has shown 3 strains of Congo virus (Congo 3010, Uganda K2/61, Pakistan JD 206) to be antigenically indistinguishable from each other and from the Drosdov strain of Crimean hemorrhagic fever (CHF) by CF tests. NT and agar gel precipitin tests confirm this relationship.

Hazara virus found to be related to but distinct from Congo virus by NT [20] and C (see HAZ registration). Also related by HI [19].

A low-titered relationship by CF, fluorescent antibody and indirect HA demonstrated between CON and NSD viruses [23], [24]. SIRACA has decided that these relations are no greater than those used to establish the Bunyamwera Supergroup. The CON and NSD antigenic groups should be kept as two distinct serogroups.

Following the above observations, intergroup relationships were demonstrated for members of the above two serogroups as well as for members of the DGK, HUG, QYB and SAK serogroups [30].

Section VI - Biologic Characteristics

Virus Source (all VERTEBRATE isolates)
blood (M)(LV), liver (LV), liver and spleen pool (LV)

Lab Methods of Virus Recovery (ALL ISOLATIONS)
newborn mice and weaning mice

Cell system (a)	Virus passage history (b)	Evidence of Infection						
		CPE			PLAQUES			Growth Without CPE +/- (g)
		Day (c)	Extent (d)	Titer TCD50/ml (e)	Day (c)	Size (f)	Titer PFU/ml (e)	
LLC-MK2 (CL)	3010 SM 6 TC 1				5-7	Plaques	4.2**	
Vero (CL)						No plaques		
Vero (CL)	SM 2		No CPE	4.5**				+
BHK-21 (CL)			No CPE	6.5				+
Ae aegypti (CL)			No CPE					-
Ae albopictus (CL)			No CPE					-
LLC-MK2 (CL)	SM6 BHK 1	4	2+	8.5 (12)				

Produces persistent infection without CPE in LLC-MK2 cells when media changed regularly. These chronically infected cells after 6-8 transfers were resistant to superinfection (plaque challenge) with Sindbis, Catu, Candiru, Chenuda, Soldado, and Congo viruses but susceptible to VS-Indiana and Cocal viruses (T. Stim. Personal Communication.)

** Expressed in dex

Section VII - Natural Host Range (Additional text can be added below table)

Vertebrate (species and organ) and arthropod	No. isolations/No. tested	No. with antibody/No. tested Test used	Country and region
Man	2; 3	*	(Stanleyville) Kisangini, Zaire; Iraq (27)
Man	10; 1		Entebbe, Uganda; Transvaal, South Africa (28)
Man	numerous	17-587 AGD	USSR (9); Hungary (20)
Man (blood)	5		Nosocomial outbreak,

Cow	1		Rawalpindi, Pakistan (26)
Cow	4/49		Ibadan, Nigeria
Goat	1		
Hedgehog (<i>Atelerix spiculus</i>)	1/38		Dada, Nigeria
<i>Hyalomma rufipes</i>	1		Ibadan, Nigeria
<i>H. impeltatum</i>	1		Kano, Nigeria
<i>H. truncatum</i>	2		Ibadan, Nigeria
<i>H. excavatum</i>	1		Sokoto, Nigeria
<i>Amblyomma variegatum</i>	1		Upper Ogun, Nigeria
<i>Boophilus decoloratus</i>	21		Ibadan, Nigeria
<i>Hyalomma</i> spp.	1		West Pakistan (16)
<i>Hyalomma</i> spp.	1		USSR
<i>Culicoides</i> spp.	1		Ibadan, Nigeria
<i>H. truncatum</i>	2		Senegal (15)
<i>H. rufipes</i>	2		
<i>A. variegatum</i>	1		Ankole Dist., Uganda (17)
<i>Hyalomma nitidum</i>	1/3 pools		Central African Republic (21)
<i>Rhipicephalus bursa</i>	1		Vergina, Macedonia, Greece (25)
<i>Hyalomma impeltatum</i>	1		Ethiopia (31)
<i>Alveonassus laborensis</i> (engorged larvae)	1		Iran (29)
Various animals		0/169 AGD	Hungary (22)

* Precipitating and NT antibody frequently found in sera of cattle, horses, sheep, and hares in Crimean hemorrhagic fever foci (13).

Section VIII - Susceptibility to Experimental Infection (include viremia)

Experimental host and age	Passage history and strain	Inoculation Route-Dose	Evidence of infection	AST (days)	Titer log ₁₀ /ml
mice (nb)	SMB 35	ic 0.03	paralysis, death	5-7	
mice (nb)		ip 0.03	death		
mice (nb)		sc			
mice (wn)	SMB 3 IbAn 7620	ic 0.03	death	4-7	
mice (wn)		ip			
calf (9-10 mo)		sc 3-4 ml	viremia, days 1-5		

Section IX - Experimental Arthropod Infection and Transmission

Arthropod species & virus source(a)	Method of Infection log ₁₀ /ml (b)		Incubation period (c)		Transmission by bite (d)		Assay of arthropod, log ₁₀ /ml (e)		
	Feeding	Injected	Days	°C	Host	Ratio	Whole	Organ	System
Hyalomma rufipes (ad) IbAn 7620, SM 3	Fed on viremic calf, virus recovered from tick after 12 days of attachment and 18 days after dropping. (Experiments carried out by Virus Lab., Univ. of Ibadan.)								

Section X - Histopathology

Character of lesions (specify host)

mice: severe cellular damage in the hippocampus

Inclusion Bodies

Intranuclear

Organs/Tissues Affected

brain (LV)

Category of tropism

Neurotropic

Section XI - Human Disease

In Nature

Residual

Death

Significant

Significant

Subclinical

Overt Disease

Significant

Clinical Manifestations

fever, headache, prostration, stiff neck, CNS signs (including encephalitis), hemorrhagic signs, and vomiting

Number of Cases

12 in Africa (1); hundreds in USSR (9)

Category (i.e. febrile illness, etc.)

Hemorrhagic fever; febrile illness

Section XII - Geographic Distribution

Known (Virus detected)

Suspected (Antibody only detected)

Section XIII - References

1. SIMPSON, D.I.H., et al. 1967. The E. African Med. J. 44:87-92.
2. WOODALL, J.P., et al. 1967. The E. African Med. J. 44:93-983.
3. MASON, P.J., 1957. E. Afr. Virus Res. Inst. Rep. No. 7, p. 23.
4. WEINBREN, M.P., et al. 1959. E. Afr. Virus Res. Inst. Rep. No. 9:7-10.
5. WILLIAMS, M.C. and WOODALL, J.P. 1960. E. Afr. Virus Res. Inst. Rep. No. 10:30-32.
6. WOODALL, J.P. and WILLIAMS, M.C. 1961. E. afr. Virus Res. Inst. Rep. No. 11:30-22.
7. WOODALL, J.P., et al. 1962. E. Afr. Virus Res. Inst. Rep. No. 12:21-22.
8. ARDOIN, P.M.L. 1965. E. Afr. Virus Res. Inst. Rep. No. 14:52.
9. CHUMAKOV, M.P., et al. 1969. Papers presented at a practical-scientific conference in Astrakhan Oblast May 21, 1968. Institute of Poliomyelitis and Viral Encephalitiides, Academy of Medical Sciences of USSR. Astrakhan District Sanitary-Epidemiolog
10. CASALS, J. 1969. Proc. Soc. Exper. Biol. Med. 131:233-236.
11. CHUMAKOV, M.P., et al. 1968, as cited in Reference 10.
12. BUCKLEY, S.M. Presented in June 1969 in Smolenice, Czechoslovakia, International Symposium on Tick-borne Arboviruses (excluding Group B). 1971. Pp 43-52.
13. CHUMAKOV, M.P., et al. 1969. Novosibersk. Academy of Sciences of the USSR, Siberian Branch. P. 108.
14. SHOPE, R.E. and CASALS, J. Personal communication. 1969.
15. Rapport annuel de l'Institut Pasteur de Dakar. 1971, 1972.
16. BEGUM, F., et al. 1970. Amer. J. Epidem. 92:197-202.
17. E. Afr. Virus Res. Inst. Rep. 1970. 20:18.
18. CASALS, J. Personal communication. 1973.
19. CASALS, J. and TRIGNOR, G.H. 1974. Proc. Soc. Exp. Biol. Med. 145:960.
20. BUCKLEY, S.M. 1974. Proc. Soc. Exp. Biol. Med. 146:594-600.
21. Rapport annuel de l'Institut Pasteur de Bangui. 1974.
22. HORVATH, L.B. 1976. Acta Microbiol. Hung. 23:331-335.
23. DAVIES, F.C. Personal communication. Nov. 1978.
24. DAVIES, F.C., et al. 1978. J. Comp. Path. 88:001-005.
25. PAPADOPOULOS, O. and KOPTOPOULOS, G. 1978. Acta Microbiol. Hellen. 23:20-28.
26. BURNEY, M.I., et al. 1980. Am. J. Trop. Med. Hyt. 29:941-947.
27. TANTAWI, H.H., et al. 1980. Acta Virol. 24:464-467.
28. ANDRONIKOV, S., et al. 1981. Morbidity and Mortality Weekly Report. 30:349-350.
29. SUREAU, P., et al. 1980. Ann. Virol (Paris). 131:185-200.
30. CASALS, J. and TIGNOR, G.H. 1980. Intervirology 14:144-147.
31. WOOD, O.L., et al. 1978. Am. J. Trop. Med. Hyg. 27:600-604.
32. HOOGSTRAAL, H. 1979. J. Med. Ent. 15(4):307-417.

Remarks